LENZ Therapeutics, Inc. (LENZ) Wednesday announced positive results from the Phase 3 CLARITY study of its two drug candidates LNZ100 and LNZ101, for the treatment of presbyopia, the loss of eye's ability to see nearby objects. The company's shares were up more than 20 percent in pre-market at $26.10.
In the Phase 3 CLARITY 1 and 2 trials, the primary endpoint was met after 71 percent of participants dosed with LNZ100 achieved three-lines or greater improvement at 3 hours.
The company has chosen LNZ100 as its lead drug candidate. While LNZ101 also showed similar results, it was not superior to LNZ100.
LENZ Therapeutics plans to submit a New Drug Application for LNZ100 in mid-2024.
Shares of LENZ Therapeutics had closed at $21.01 on Tuesday. The stock has been trading in the range of $2.01 - $24.05 in the last 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.